GlassScriptPhysician profile
Colleen M Okeeffe
NPI 1366943755
$1,673.73
in general payments reported to CMS, 2019-2025
15 companies · $881 in 2025
The $881 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.89 · 2022: $118 · 2023: $86.97 · 2024: $571 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $489.92 | 2023-2025 | |
| Aop Health US, LLC | $264.64 | 2025 | Rapiblyk |
| E.R. Squibb & Sons, L.L.C. | $238.98 | 2023-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $155.76 | 2024-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $122.36 | 2022-2025 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $110.30 | 2024 | Arcalyst |
| Amgen INC. | $70.94 | 2024-2025 | Repatha, Repatha |
| Pfizer INC. | $48.89 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $45.78 | 2024-2025 | Farxiga, Lokelma |
| Bridgebio Pharma, INC. | $32.87 | 2025 | Attruby |
| Edwards Lifesciences Corporation | $27.96 | 2023 | |
| Scpharmaceuticals INC. | $19.11 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.94 | 2024 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $15.44 | 2024 | |
| Esperion Therapeutics, INC. | $13.84 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Okeeffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.